LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer.

ABSTRACT: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression. The mechanisms that lead to a shift from initial therapeutic sensitivity to ultimate therapeutic resistance are poorly understood. Although the SCLC genomic landscape led to the discovery of promising agents targeting genetic alterations that were already under investigation, results have been disappointing. Achievements in targeted therapeutics have not been observed for over 30 years. Therefore, the underlying disease biology and novel targets urgently require a better understanding. Epigenetic regulation is deeply involved in the cellular plasticity that could shift tumor cells to the malignant phenotype. We have focused on a histone modifier, LSD1, that is overexpressed in SCLC and i

SUBMITTER: Jotatsu T 

PROVIDER: S-EPMC5614583 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature